argenx SE Stock price

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Real-time Euronext Bruxelles 04:46:14 2024-03-28 am EDT 5-day change 1st Jan Change
370.2 EUR +0.54% Intraday chart for argenx SE -0.56% +7.66%
Sales 2024 * 1.67B 1.8B Sales 2025 * 2.27B 2.45B Capitalization 21.87B 23.59B
Net income 2024 * -125M -135M Net income 2025 * 232M 250M EV / Sales 2024 * 11.7 x
Net cash position 2024 * 2.27B 2.45B Net cash position 2025 * 2.42B 2.61B EV / Sales 2025 * 8.57 x
P/E ratio 2024 *
-149 x
P/E ratio 2025 *
111 x
Employees 1,148
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.88%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.30%
1 week-0.70%
Current month+7.60%
1 month+0.22%
3 months+6.40%
6 months-18.28%
Current year+7.51%
More quotes
1 week
359.70
Extreme 359.7
378.30
1 month
322.50
Extreme 322.5
378.30
Current year
322.50
Extreme 322.5
381.10
1 year
271.00
Extreme 271
494.10
3 years
201.40
Extreme 201.4
494.10
5 years
93.05
Extreme 93.05
494.10
10 years
6.23
Extreme 6.23
494.10
More quotes
Managers TitleAgeSince
Founder 52 07-12-31
Director of Finance/CFO 54 21-05-31
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Director/Board Member 71 17-04-25
Director/Board Member 74 15-05-12
Director/Board Member 63 16-04-27
More insiders
Date Price Change Volume
24-03-28 370.2 +0.54% 2 081
24-03-27 368.2 +0.60% 50,365
24-03-26 366 0.00% 44,726
24-03-25 366 -1.11% 40,864
24-03-22 370.1 -0.48% 61,295

Real-time Euronext Bruxelles, March 28, 2024 at 04:31 am EDT

More quotes
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
368.2 EUR
Average target price
439.3 EUR
Spread / Average Target
+19.31%
Consensus
  1. Stock
  2. Equities
  3. Stock argenx SE - Euronext Bruxelles